View Clinical Trial (Medical Research Study)


Compliance to Vaginal Dilation Therapy in Patients Who Have Undergone Radiation Therapy For Stage IB, Stage IIA, Stage IIB, Stage IIIA, or Stage IIIB Cervical Cancer or Stage IA, Stage IB, Stage IIA, or Stage IIB Endometrial Cancer - NCT00735514-44060(Clinical Trial 236664)



ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.


Signup

City:  Cleveland
State:  
OH
Zip Code: 44060
Conditions: Cervical Cancer - Endometrial Cancer - Radiation Toxicity - Sexuality and Reproductive Issues
Purpose: RATIONALE: Understanding how well patients comply with their treatment regimen may help doctors determine best treatment and ongoing care for future patients. PURPOSE: This phase I study is looking at compliance with vaginal dilation therapy in women who have undergone radiation therapy for stage IB, stage IIA, stage IIB, stage IIIA, or stage IIIB cervical cancer or stage IA, stage IB, stage IIA, or stage IIB endometrial cancer.
Study summary: OBJECTIVES: Primary - To determine adherence to vaginal dilation therapy after radiotherapy in patients with early-stage IB grade 2-IIIB cervical cancer or stage IA grade 3-IIB endometrial cancer. - To identify demographic, medical, and psychosocial factors associated with adherence to recommendations for vaginal dilation in these patients. - To describe the sexual, marital, and non-marital dyadic functioning of these patients. OUTLINE: Patients from the IMPAC registry in Radiation Oncology at the University Hospitals Case Medical Center, Ireland Cancer Center complete questionnaires online or by mail. Questionnaires include the Vaginal Dilation Adherence questionnaire, the Sexual Function-Vaginal Changes Questionnaire, the Dyadic Satisfaction questionnaire, and the Physician/Nurse Recommendation of Vaginal Dilation questionnaire.
Criteria: DISEASE CHARACTERISTICS: - History of early-stage IB grade 2-IIIB cervical cancer or stage IA grade 3-IIB endometrial cancer - Meets the following criteria: - Received radiotherapy for this disease - Treated within the last 3 years and followed for at least 6 months PATIENT CHARACTERISTICS: - Able to read and understand English - Currently with or without a sexual partner - No history of other cancers - No other potentially life-threatening disease PRIOR CONCURRENT THERAPY: - See Disease Characteristics
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
Trials Alerts: If you would like to be notified of new clinical trials as they become available please register for a free account.

Data Source: ClinicalTrials.gov
Date Processed: May 21, 2010
Modifications to
this listing:
Only selected fields are shown, please use the link above to view all information about this clinical trial.